Clinical trial
A Single-arm, Open-label, Multi-center Phase Ib/II Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma(CLL/SLL)
NCT04808570 is registered in ClinicalTrials.gov with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-arm, Open-label, Multi-center Phase Ib/II Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma(CLL/SLL)
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- June 5, 2021
- Completion date
- November 22, 2023
- Enrollment
- 23 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.
relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma